Comments on: Amgen’s Bid to Make Cancer Drug “Personalized” Lacks Data, FDA Panel Says http://www.xconomy.com/seattle/2008/12/16/amgens-bid-to-make-cancer-drug-personalized-shot-down-by-fda-panel/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Anon http://www.xconomy.com/seattle/2008/12/16/amgens-bid-to-make-cancer-drug-personalized-shot-down-by-fda-panel/comment-page-1/#comment-43212 Anon Wed, 17 Dec 2008 22:25:33 +0000 http://www.xconomy.com/?p=6987#comment-43212 From same Reuters story linked in piece: "Despite ImClone and Amgen's request, the FDA did not seek advice on Erbitux and Vectibix but cited them as examples." From same Reuters story linked in piece:

“Despite ImClone and Amgen’s request, the FDA did not seek advice on Erbitux and Vectibix but cited them as examples.”

]]> By: Why Xconomy works « A Man With A Ph.D. http://www.xconomy.com/seattle/2008/12/16/amgens-bid-to-make-cancer-drug-personalized-shot-down-by-fda-panel/comment-page-1/#comment-43190 Why Xconomy works « A Man With A Ph.D. Wed, 17 Dec 2008 18:48:24 +0000 http://www.xconomy.com/?p=6987#comment-43190 [...] Xconomy works December 17, 2008 — Richard Amgen’s Bid to Make Cancer Drug “Personalized” Lacks Data, FDA Panel Says: [Via Xconomy Life Sciences Feed] Biotech, cancer, Personalized Medicines Luke Timmerman [...] [...] Xconomy works December 17, 2008 — Richard Amgen’s Bid to Make Cancer Drug “Personalized” Lacks Data, FDA Panel Says: [Via Xconomy Life Sciences Feed] Biotech, cancer, Personalized Medicines Luke Timmerman [...]

]]> By: Richard http://www.xconomy.com/seattle/2008/12/16/amgens-bid-to-make-cancer-drug-personalized-shot-down-by-fda-panel/comment-page-1/#comment-43189 Richard Wed, 17 Dec 2008 18:37:26 +0000 http://www.xconomy.com/?p=6987#comment-43189 It's articles like this that display the real difference between Xconomy and MSM. There is a fair assessment of what happened and why, with the background, links, etc. needed for a dedicated reader to gain much more information. Less spin and more perspective. I think that this drug will be a great example of 'personalized' medicine but we are early in this new realm and the FDA wants to be extra certain. If Amgen and Lilly can produce really strong statistical numbers for this drug in people with a specific genetic background, it will be a great step forward towards our understanding of why some drugs work only for some groups of people. It’s articles like this that display the real difference between Xconomy and MSM. There is a fair assessment of what happened and why, with the background, links, etc. needed for a dedicated reader to gain much more information. Less spin and more perspective.

I think that this drug will be a great example of ‘personalized’ medicine but we are early in this new realm and the FDA wants to be extra certain.

If Amgen and Lilly can produce really strong statistical numbers for this drug in people with a specific genetic background, it will be a great step forward towards our understanding of why some drugs work only for some groups of people.

]]>